Summary: Psymposia reports on the impact that coronavirus is having on clinical trials, stating, “almost all clinical psychedelic drug research is being affected in some way or another by COVID-19.” The article reviews public statements from psychedelic research organizations explaining how they are pivoting and which priorities are shifting for each organization.” In the setting of the COVID-19 pandemic, the safety of our study staff and participants is of paramount importance,” explains Alia Lilienstein, M.D., M.P.H., Medical Director of MAPS Public Benefit Corporation (MAPS PBC).
Originally appearing here.